The Zimmerman-McLean-Foster hypothesis: 25 Years later

British Journal of Ophthalmology

Volumn 88, Issue 7, 2004, Pages 962-967

  Singh, A D ^a   Rennie, I G ^b   Kivela, T ^c   Seregard, S ^d   Grossniklaus, H ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d ST ERIK S EYE HOSPITAL   (Sweden)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEAM THERAPY; CANCER MORTALITY; CANCER SIZE; CANCER SURVIVAL; CHOROID MELANOMA; CLINICAL TRIAL; CORRELATION ANALYSIS; ENUCLEATION; FINLAND; GROWTH RATE; HUMAN; HYPOTHESIS; LIFE EXPECTANCY; METASTASIS; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; SWEDEN; THEORETICAL MODEL; TUMOR GROWTH; UNITED STATES; UVEA MELANOMA;

BRACHYTHERAPY; CHOROID NEOPLASMS; EYE ENUCLEATION; FINLAND; HUMANS; MELANOMA; PROTONS; SWEDEN; UNITED STATES;

EID: 3042749820     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.029058     Document Type: Review

References (54)

1. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol 1978;62:420-5.
2. Zimmerman LE, McLean IW. An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol 1979;87:741-60.
3. McLean IW, Zimmerman LE, Foster WD. Survival rates after enucleation of eyes with malignant melanoma. Am J Ophthalmol 1979;88:794-7.
4. Gragoudas ES. The Bragg peak of proton beams for treatment of uveal melanoma. Intl Ophthalmol Clin 1980;20:123-33.
5. Lommatzsch PK. Beta-irradiation of choroidal melanoma with 106Ru/106Rh applicators. 16 Years' experience. Arch Ophthalmol 1983;101:713-17.
6. Char DH. Therapeutic options in uveal melanoma. Am J Ophthalmol 1984;98:796-9.
7. Augsburger JJ, Gomel JW, Lauritzen K, Brady LW. Cobalt-60 plaque radiotherapy vs enucleation for posterior uveal melanoma. Am J Ophthalmol 1990;109:585-92.
8. Foulds WS, Damato BE, Burton RL. Local resection versus enucleation in the management of choroidal melanoma. Eye 1987;1:676-9.
9. Paul EV, Parnell BL, Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin 1962;2:387-402.
10. Callender GR. Malignant melanotic tumors of the eye: a study of histologic types in all cases. Trans Am Acad Ophthalmol Otolaryngol 1931;36:131-42.
11. Wagoner MD, Albert DM. The incidence of metastases from untreated ciliary body and choroidal melanoma. Arch Ophthalmol 1982;100:939-40.
12. Pach JM, Robertson DM. Metastasis from untreated uveal melanomas. Arch Ophthalmol 1986;104:1624-5.
13. Rankin SJ, Johnston PB. Metastatic disease from untreated choroidal and ciliary body melanomas. Int Ophthalmol 1991;15:75-8.
14. McLean IW, Foster WD, Zimmerman LE, et al. Inferred natural history of uveal melanoma. Invest Ophthalmol Vis Sci 1980;19:760-70.
15. Zimmerman LE, McLean IW. The natural course of untreated uveal melanomas. Doc Ophthalmol 1980;15:75-82.
16. Augsburger JJ. Impact of enucleation on survival in posterior uveal melanoma: a reappraisal of the Zimmerman hypothesis. In: Cohen FJ, eds. Year book of ophthalmology.St. Louis: Mosby-Year Book, 1990:123-6.
17. Singh AD, Tapham A. Survival rate with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:962-5.
18. Reis L, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1997. Bethesda, MD: National Cancer Institute, 2000.
19. http://seer.cancer.gov. Data quality, 2001.
20. Bergman L, Seregard S, Nilsson B, et al. Uveal melanoma survival in Sweden 1960 to 1998. Invest Ophthalmol Vis Sci 2003;44:3282-7.
21. Kujala E, Mäkitie T, Kivelä T. Very long term prognosis of malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-9.
22. Manschot WA. Choroidal melanoma. Enucleation or observation? A new approach. Arch Ophthalmol 1980;98:71-7.
23. Niederkorn JY. Enucleation-induced metastasis of intraocular melanomas in mice. Ophthalmology 1984;91:692-700.
24. Adams KS, Abramson DH, Ellsworth RM, et al. Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rotes. Br J Ophthalmol 1988;72:494-7.
25. Augsburger JJ, Schneider S, Freire J, et al. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 1999;237:558-67.
26. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choraidal melanama, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol 2001;119:969-82.
27. Puusaari I, Heikkonen J, Summanen P, et al. Iodine brachytherapy as an alternative to enucleation for large melanomas. Ophthalmology 2003;110:2223-34.
28. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990;97:769-77.
29. Kroll S, Char DH, Quivey J, et al. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma. Ophthalmology 1998;105:2035-45.
30. Augsburger JJ, Lauritzen K, Gamel JW, et al. Matched group study of surgical resection versus cobalt-60 plaque radiotherapy for primary choroidal or ciliary body melanoma. Ophthal Surg 1990;21:682-8.
31. Bornfeld N, Gragoudas ES, Hopping W, et al. Local resection in the mangement of choroidal melanoma. Proceedings of the international symposium on tumours of the eye. Amsterdam: Kugler, 1991.
32. Straatsma BR, Fine SL, Earle JD, et al. Enucleation versus plaque irradiation for choroidal melanoma. Ophthalmology 1988;95:1000-4.
33. Anonymous. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no 10. Am J Ophthalmol 1998;125:779-96.
34. Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology 2001;108:829-30.
35. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-94.
36. DeVita VTJ. Principles of cancer management:chemotherapy. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer:principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997.
37. O'Brian J. Invited commentary. Ophthalmology 2001;108:831-2.
38. Augsburger JJ, Gonder JR, Amsel J, et al. Growth rates and doubling times of posterior uveal melanomas. Ophthalmology 1984;91:1709-15.
39. Gass JDM. Comparison of uveal melanoma growth rates with mitotic index and mortality. Arch Ophthalmol 1985;103:924-31.
40. Char DH, Kroll S, Phillips TL. Uveal melanoma. Growth rate and prognosis. Arch Ophthalmol 1997;115:1014-18.
41. Manschot WA, Van Peperzeel HA. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982;13:1147-8.
42. Manschot WA, van Strik R. Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review. Int Ophthalmol 1992;16:91-9.
43. Eskelin S, Pyrhonen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000;107:1443-49.
44. Eskelin S, Kivela T. Reply: Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2001;108:830-1.
45. Hanahan D, Weinberg RA. The hallmark of cancer. Cell 2000;100:57-70.
46. Rennie IG. Uveal melanoma: the past, the present and the future. Eye 1997;11:255-64.
47. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosome 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes and Cancer 1997;19:22-8.
48. McLean IW. Prognostic features of uveal melanoma. Ophthalmol Clin N Am 1995;8:143-53.
49. Jager MH, Hurks MH, Levitskaya J, et al. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol 2002;63:444-51.
50. Kramer TR, McLean IW, Dithmar S, et al. Vascularization of liver metastases of human uveal melanoma. Inv Ophthalmol Vis Sci 2000;41:5381.
51. Arbiser JC. Melanoma. Lessons from metastasis. Arch Dermatol 1998;134:1027-8.
52. Yang H, Dithmar S, Grossniklaus HE. Low dose angiostatin decreases hepatic micrometastasis in murine ocular melanoma model. Invest Ophthlamol Vis Sci 2003 (ARVO abstract No 933).
53. Folkman J. Tumor angiogenesis. In: Bast Jr RC, Kufe DW, Pollock RE, eds. Cancer medicine.5th ed. Hamilton, Ontario: BC Decker, 2000:132-52.
54. Apte RS, Niederkorn JY, Mayhew E, et al. Angiostatin produced by certain primary uveal melanoma cell lines impedes the development of liver metastases. Arch Ophthalmol 2001;119:1805-9.